Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics, Inc. (COYA)
Company Research
Source: Business Wire
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan.Dear Fellow Stockholder,Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the “innovation and get-it-done” culture in Coya’s DNA. We have made tremendous strides in 2024, repeatedly executing on our promises. As I look to 2025, I am confident that our nimble and highly experienced team will continue to exceed expectations.I have spent my entire 25-year career in the biotech space, and I believe that Coya has the most promise of any company that I have represented. I truly believe our novel science, strong clinical proof of concept data, phar
Show less
Read more
Impact Snapshot
Event Time:
COYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COYA alerts
High impacting Coya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
COYA
News
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.MarketBeat
- Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial ResultsBusiness Wire
- Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive OfficerBusiness Wire
COYA
Sec Filings
- 11/20/24 - Form S-3
- 11/14/24 - Form 4
- 11/13/24 - Form 4
- COYA's page on the SEC website